Aplastic Anemia Research Study
|
Alemtuzumab (Campath) for Refractory or Relapsed Severe Aplastic Anemia
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Severe Aplastic Anemia (SAA). The study drug, a monoclonal antibody, may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on transfusions. Subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with SAA and have received prior immunosuppressive therapy and have either failed to respond or have relapsed following treatment, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Campath versus r-ATG/CsA versus h-ATG/CsA for previously untreated Severe Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute of the National Institutes of Health, a part of the Department of Health and Human Services, are investigating methods of treatment for severe aplastic anemia. Hematologists are comparing the effectiveness of three immunosuppressive regimens in previously untreated (no prior immunosuppressive therapy) patients. The study may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If determined eligible to participate, you (your child) will be selected by a process based on chance to receive one of threee therapies.
If you have been diagnosed with severe aplastic anemia and at least 2 years old, you (your child) may be able to participate in this clinical trial. To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Daclizumab for Aplastic Anemia
|
If you or someone you know has been diagnosed with aplastic anemia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Hepatitis-Associated Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), a part of the Department of Health and Human Services (DHHS) are conducting laboratory studies on blood, bone marrow, stool and/or liver tissue samples from subjects with hepatitis-associated aplastic anemia to improve our understanding of the disease and possibly identify one or more causative viral agents.
If you or someone you know has been diagnosed with hepatitis-associated aplastic anemia you may be able to participate in this clinical trial. To find out if you qualify, please contact our research coordinator at (301) 496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Randomized Trial of Campath versus r-ATG/CsA for Severe Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute of the National Institutes of Health, a part of the Department of Health and Human Services, are investigating a new method of treatment for severe aplastic anemia. Hematologists are comparing the effectiveness of a new immunosuppressive treatment (Campath-1H) with rabbit ATG and Cyclosporine (CsA) therapy for patients with severe aplastic anemia. The study may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
If you are determined eligible to participate, you will be selected by a process based on chance to receive either (1) Campath-1H for 10 days or (2) rabbit ATG for 5 days + CsA for 6 months.
If you have been diagnosed with severe aplastic anemia and are over the age of 14, you may be able to participate in this clinical trial. To find out if you qualify, please contact our coordinator at (301) 496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Rituximab (Rituxan) for Moderate Aplastic Anemia
|
If you or someone you know has been diagnosed with aplastic anemia you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered monoclonal antibody therapy, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If you are determined eligible to participate, you will be treated with an infusion of rituximab once every week for a total of 4 doses and then followed to evaluate for response
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Aplastic Anemia Research Study
|
Stem Cell Transplant for Patients with Aplastic Anemia
|
If you have been diagnosed with aplastic anemia or paroxysmal nocturnal hemoglobinuria (PNH), you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Umbilical Cord Transplant to Treat Severe Aplastic Anemia
|
If you (or someone you know) has been diagnosed with aplastic anemia, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective for a wide number of diseases and disorders. In this study, we will evaluate the safety and effectiveness using a different type of stem cell transplant procedure, specifically, co-infusion of peripheral blood stem cells from a family member and cord blood stem cells from an unrelated donor.
You must have family member who is willing to participate as a stem cell donor as well as the availability of an HLA matched umbilical cord blood unit (the NIH will conduct the search and procurement) in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 594-8013 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute